The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Real-world dose de-escalation of teclistamab in patients with R/R myeloma
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses real-world dose de-escalation of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma (MM). While the MajesTEC-1 trial (NCT04557098) demonstrated the efficacy of teclistamab, it also highlighted a high risk of infection. Patients at Dr Usmani’s center who underwent dose de-escalation after three treatment cycles maintained a sustained response at six months, indicating this was an effective strategy to mitigate infection risk. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Abbvie, Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda. Consulting: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Gracell Therapeutics, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
